Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) Debt to Equity: 2012-2022

Historic Debt to Equity for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2022 value amounting to -$2.38.

  • RedHill Biopharma's Debt to Equity fell 125.27% to -$2.38 in Q4 2022 from the same period last year, while for Dec 2022 it was -$2.38, marking a year-over-year decrease of 125.27%. This contributed to the annual value of -$14.4 million for FY2023, which is 603949698.64% down from last year.
  • Latest data reveals that RedHill Biopharma reported Debt to Equity of -$2.38 as of Q4 2022, which was up 100.00% from -$11.8 million recorded in Q3 2022.
  • In the past 5 years, RedHill Biopharma's Debt to Equity registered a high of $17.4 million during Q4 2019, and its lowest value of -$59.4 million during Q2 2020.
  • Moreover, its 3-year median value for Debt to Equity was $0.04 (2020), whereas its average is -$8.1 million.
  • Per our database at Business Quant, RedHill Biopharma's Debt to Equity soared by 14,601,111,011.11% in 2018 and then crashed by 148,412,500,100.00% in 2020.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Debt to Equity stood at $12.7 million in 2018, then surged by 37.60% to $17.4 million in 2019, then tumbled by 100.00% to $5.87 in 2020, then surged by 60.50% to $9.42 in 2021, then crashed by 125.27% to -$2.38 in 2022.
  • Its last three reported values are -$2.38 in Q4 2022, -$11.8 million for Q3 2022, and -$1.8 million during Q2 2022.